Search

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Click here to read more about how the use of JARDIANCE reduced the risk of kidney disease progression in adults with established CVD and T2D.

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

Clinical Pharmacology

Boehringer Ingelheim is proud to offer a new two-year fellowship within Clinical Pharmacology. Click here to find out more.

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.

First half 2019: High levels of investment in R&D and robust organic growth

Poultry vaccine site in Georgia continues to reduce carbon emissions

Going carbon neutral has resulted in measurable, positive impacts. From 2021 to 2022, the Gainesville site reduced its CO2 emissions by 23 percent – nearly 700 fewer tons of CO2 emissions are released into the atmosphere

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Ivermectin in Animal Health products and COVID-19

Swine

Real-world data announced for adults with type 2 diabetes

Two analyses of the U.S. data from the EMPRISE real-world study show that Jardiance (empagliflozin) tablets was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adult

The liver and its vital connection to our overall health

How the liver is part of our interconnected cardiovascular, renal and metabolic system and why we need to look after it

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

Regulatory Affairs

Read more on BI's two-year fellowship within Regulatory Affairs. The Fellow will obtain in-depth and hands-on experience in regulatory strategy.

FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD

Data Shows Jardiance® (empagliflozin) Cardiorenal Risk Reductions | Boehringer Ingelheim US

The EMPA-REG OUTCOME® trial shows JARDIANCE reduces CV and renal risk in adults with T2D & known CV disease. View ISI, PI & Med Guide.

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes

Federal and State Laws

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

Prescription Digital Therapeutics a New Frontier in Mental Health Care

Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US

FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers